Status:
COMPLETED
CNS Sarcoidosis and Acthar Gel
Lead Sponsor:
University of Maryland, Baltimore
Collaborating Sponsors:
Mallinckrodt
Conditions:
CNS Sarcoidosis
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The purpose of this study is to see if treatment with H.P. Acthar® Gel will result in the improvement and long-term stabilization of clinical and radiographic abnormalities that occur in patients with...
Detailed Description
Sarcoidosis is a chronic and frequently progressive systemic disease that affects the central nervous system (CNS) in approximately 5% of patients. The hallmark of the disease is the development of ch...
Eligibility Criteria
Inclusion
- A highly probable diagnosis of sarcoidosis, as determined using the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Sarcoidosis Organ Assessment Instrument (Judson et al., 2014), with involvement not limited to the central nervous system.
- At the time of enrollment, a history of clinical deterioration based on the development of new symptoms or worsening previously present symptoms with confirmation by clinical examination and objective clinical testing.
- If on steroids, on a stable dose of the medication for at least 3 months.
Exclusion
Key Trial Info
Start Date :
May 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2020
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT02298491
Start Date
May 1 2016
End Date
November 1 2020
Last Update
April 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland, Baltimore
Baltimore, Maryland, United States, 21201